Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bioterror “Strategic Investor” Initiative Must Be Resolved As House, Senate Pass Dueling Bills

This article was originally published in The Pink Sheet Daily

Executive Summary

House- and Senate-passed bills reauthorizing the 2006 Pandemic and All-Hazards Preparedness Act are similar in many respects in their efforts to accelerate medical countermeasure development. However, the House bill lacks a Senate provision that would allow HHS to contract with a non-profit entity to invest in companies developing countermeasures.

You may also be interested in...



Medical Countermeasures: Long-Term Funding Could Spur More Development Work

Chimerix CEO tells Congress allocating Project Bioshield a multi-year funding stream would provide more long-term certainty for countermeasure sponsors.

Countermeasures May Need More Incentives Than Vouchers, Gottlieb Says

With priority review voucher values falling, Congress may want to think about additional incentives for medical countermeasure development, Commissioner Gottlieb tells Senate committee.

Legislative Outlook: Animal Drug User Fee Could Carry Human Drug Proposals

ADUFA reauthorization may become the vehicle to move track and trace and compounding legislation. Reimbursement changes to mitigate shortages appear less likely.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS073860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel